The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Capitalizing on these technological breakthroughs, BlueRock are advancing novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies, across neurology, cardiology and immunology. Lead program is a first-in-class cellular therapy in development for the treatment of Parkinson’s disease.

Further Activities to have a look at